Elite Pharma Inc (ELTP) 0.2551 $ELTP FDA accept
Post# of 64200
Posted On: 03/04/2015 6:10:25 PM
Elite Pharma Inc (ELTP) 0.2551 $ELTP
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 116.19 (+1.34), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09), EGLT: 15.36 (unch), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08), ABBV: 60.27 (+0.65), TEVA: 56.56 (+0.10), ALKS: 70.80 (-2.00), ACUR: 0.74 (-0.08)
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2015 - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 2:31PM CST
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 116.19 (+1.34), LCI: 62.28 (+0.01), EGLT: 15.36 (unch), ACT: 296.14 (-0.09), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08), ABBV: 60.27 (+0.65), TEVA: 56.56 (+0.10), ALKS: 70.80 (-2.00), ACUR: 0.74 (-0.08)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Tue Feb 17, 4:56PM CST
Revenues Increase 8.5% Over Prior Quarter
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
GlobeNewswire - Tue Feb 17, 4:55PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an abuse deterrent opioid product. Elite has submitted a study protocol to the FDA and dosing for the study is expected to begin shortly after the FDA comments on the protocol are received by Elite. The Company anticipates that it will receive the FDA comments by mid-March and that dosing will take approximately eight weeks to complete.
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
GlobeNewswire - Thu Feb 12, 1:49PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, February 18, 2015 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.47 (-0.01)
Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 296.14 (-0.09), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 15.36 (unch), ACT: 296.14 (-0.09), PFE: 34.64 (+0.08), ACUR: 0.74 (-0.08)
Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules
GlobeNewswire - Thu Jan 15, 9:46AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced the first shipments of generic Isradipine 2.5 mg and 5.0 mg capsules. Isradipine is a calcium channel blocker prescribed for hypertension. Annual U.S. sales for immediate release Isradipine 2.5 mg and 5.0 mg capsules are approximately $5.5 million for the twelve months ending June 30, 2014 according to IMS Health Data. Currently there is a single generic product marketed in the U.S for immediate release Isradipine 2.5 mg and 5.0 mg capsules.
Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property protection covering the Company's abuse deterrent technology with the issuance of a second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance continues to expand the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite's twice daily abuse-deterrent oxycodone product which utilizes Elite's proprietary pharmacological abuse-deterrent technology.
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST
Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.
Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.
Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.
Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 116.19 (+1.34), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09), EGLT: 15.36 (unch), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08), ABBV: 60.27 (+0.65), TEVA: 56.56 (+0.10), ALKS: 70.80 (-2.00), ACUR: 0.74 (-0.08)
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2015 - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 2:31PM CST
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 116.19 (+1.34), LCI: 62.28 (+0.01), EGLT: 15.36 (unch), ACT: 296.14 (-0.09), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08), ABBV: 60.27 (+0.65), TEVA: 56.56 (+0.10), ALKS: 70.80 (-2.00), ACUR: 0.74 (-0.08)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Tue Feb 17, 4:56PM CST
Revenues Increase 8.5% Over Prior Quarter
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
GlobeNewswire - Tue Feb 17, 4:55PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an abuse deterrent opioid product. Elite has submitted a study protocol to the FDA and dosing for the study is expected to begin shortly after the FDA comments on the protocol are received by Elite. The Company anticipates that it will receive the FDA comments by mid-March and that dosing will take approximately eight weeks to complete. Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, February 18, 2015
GlobeNewswire - Thu Feb 12, 1:49PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, February 18, 2015 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks. IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.47 (-0.01)
Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 296.14 (-0.09), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 15.36 (unch), ACT: 296.14 (-0.09), PFE: 34.64 (+0.08), ACUR: 0.74 (-0.08)
Elite Pharmaceuticals Announces First Shipment of Generic Isradipine Capsules
GlobeNewswire - Thu Jan 15, 9:46AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced the first shipments of generic Isradipine 2.5 mg and 5.0 mg capsules. Isradipine is a calcium channel blocker prescribed for hypertension. Annual U.S. sales for immediate release Isradipine 2.5 mg and 5.0 mg capsules are approximately $5.5 million for the twelve months ending June 30, 2014 according to IMS Health Data. Currently there is a single generic product marketed in the U.S for immediate release Isradipine 2.5 mg and 5.0 mg capsules. Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property protection covering the Company's abuse deterrent technology with the issuance of a second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance continues to expand the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe. Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite's twice daily abuse-deterrent oxycodone product which utilizes Elite's proprietary pharmacological abuse-deterrent technology. Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST
Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks. Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs. Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain. Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.
(0)
(0)